HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Sulfasalazine

HCID 5339
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
599-79-1
Standard SMILES
O=C(O)c1cc(N=Nc2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O
InChIKey
NCEXYHBECQHGNR-UHFFFAOYSA-N
Molecular formula
C18H14N4O5S
Average molar mass
398.4 g/mol
Monoisotopic mass
398.06849055

Overview

Sulfasalazine (salicylazosulfapyridine) can cause cancer according to The National Toxicology Program. It can cause male reproductive toxicity according to state or federal government labeling requirements.

Names & identifiers

Preferred name
Sulfasalazine
IUPAC
2-hydroxy-5-[[4-(pyridin-2-ylsulfamoyl)phenyl]diazenyl]benzoic acid
English name
Sulfasalazine
Molecular formula
C18H14N4O5S
Molecular weight
398.39

Names & synonyms

sulfasalazine599-79-1SalicylazosulfapyridineSulphasalazineAzulfidineSalazosulfapyridineSalazopyrinBenzosulfaSulcolonSalazopyridinAsulfidineAzopyrine
Show more names
saspsulfasalazinSSZs.a.s.-500si-88
AccucolAzopyrinSalisulfSalazopiridazinReupirinw-t Sasp oralColo-PleonSalazosulfapyridin

Database identifiers

CAS
599-79-1
PubChem CID
5339
DTXSID
DTXSID0021256
ChEMBL
CHEMBL100848、CHEMBL242373
ChEBI
CHEBI:9334
UNII
3XC8GUZ6CB
Nikkaji
J2.073G

Properties

Computed structural properties

XLogP
-0.7
Topological polar surface area
150 Ų
Hydrogen bond donors
3
Hydrogen bond acceptors
9
Rotatable bonds
6
Heavy atoms
28
Formal charge
0
Complexity
657

Experimental & physicochemical properties

Drugs · 4 items

Pharmaceuticals -> Used in Switzerland

Pharmaceuticals -> Antibiotics

Pharmaceuticals -> Analgesics and anti-inflammatories

Pharmaceuticals -> Listed in ZINC15

LogP-0.13
SolubilityPractically insoluble in water
Dissociation Constants · 2 items

2.65

0.6

Collision Cross Section · 4 items

203.9 Ų [M+H]+ [CCS Type: DT; Buffer gas: N2; Ionization: APCI+; Dataset: TOXCAST; Source Identifier: DTXSID0021256]

199.36 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

200.4 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

199.7 Ų [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]

Physicochemical properties

Melting point
260 · 260-265 °C (dec.)(lit.)
Boiling point

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

Toxicology

EPA Human Health Benchmarks for Pharmaceuticals · 6 items

Sulfasalazine

46.6

197.2

Maintenance therapy dosage for adults is 2 g daily.

Data used to generate the benchmarks include the following: Lowest Daily Dose (LDD): 2000 mg/day, Lowest Therapeutic Dose (LTD): 25.0 mg/kg-day, and Screening Dose: 0.008 mg/kg-day.

10-Feb-21

Safety data

F
8
PPE
dust mask type N95 (US), Eyeshields, Faceshields, Gloves
wgk
2
rtecs
VO6250000
ridadr
3077
hs_code
2933399090
Toxicity
LD50 oral in rabbit: > 7500mg/kg
risk_code
42/43
Signal word
Danger
Symbol(GHS)
GHS08
hazard_code
Xn
safety_code
22-29/56-45
Storage Class
11 - Combustible Solids
Hazard statements
H317-H334
Hazard Classifications
Aquatic Chronic 2Carc. 2Repr. 2Resp. Sens. 1Skin Sens. 1
Precautionary statements
P261-P272-P280-P284-P302+P352-P333+P313
Hazardous Substances Data
599-79-1(Hazardous Substances Data)

Chemistry & industry

Pharmacology

ATC CodeA07EC01
Protein BindingSulfasalazine is highly bound to albumin (>99.3%) while sulfapyridine is only about 70% bound to albumin. Acetylsulfapyridine, the principal metabolite of sulfapyridine, is approximately 90% bound to plasma proteins.
Pharmacodynamics · 1 item

The mode of action of sulfasalazine or its metabolites, 5-aminosalicylic acid and sulfapyridine, is still under investigation but may be related to the anti-inflammatory and/or immunomodulatory properties that have been observed in animal and <i>in vitro</i> models, to its affinity for connective tissue, and/or to the relatively high concentration it reaches in serous fluids, the liver, and intestinal walls, as demonstrated in autoradiographic studies in animals. In ulcerative colitis, clinical studies utilizing rectal administration of sulfasalazine, sulfapyridine, and 5-aminosalicylic acid have indicated that the major therapeutic action may reside in the 5-aminosalicylic acid moiety. The relative contribution of the parent drug and the major metabolites in rheumatoid arthritis is unknown.

Mechanism of Action · 1 item

Although the exact mechanism of action of sulfasalazine is not fully understood, it is thought to be mediated through the inhibition of various inflammatory molecules. Research have found that sulfasalazine and its metabolites, mesalazine and sulfapyridine, can inhibit leukotrienes and prostaglandins by blocking the cyclo-oxygenase and lipoxygenase pathway. Specific enzymes that were investigated include phospholipase A2, cyclooxygenase-1 (COX-1), cyclooxygenase-2 (COX2), and arachidonate 5-lipoxygenase. Inhibitory activities on other non-arachidonic acid derivatives have also been observed, including PPAR gamma, NF-Kb, and IkappaB kinases alpha and beta.

Biological Half-Life · 1 item

The observed plasma half-life for intravenous sulfasalazine is 7.6 ± 3.4 hours.In fast acetylators, the mean plasma half-life of sulfapyridine is 10.4 hours while in slow acetylators, it is 14.8 hours.Due to low plasma levels produced by 5-aminosalicylic acid after oral administration, reliable estimates of plasma half-life are not possible.

Related reactions

4 records
New reaction record
HRID 1750338 reaction equation
HRID 1750338As reactant
HRID 2202207 reaction equation
HRID 2202207As reactant
HRID 2205960 reaction equation
HRID 2205960As reactant
HRID 2272552 reaction equation
HRID 2272552As reactant

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
689.3 · 689.3±65.0 °C(Predicted)
Density
1.3742 · 1.3742 (rough estimate)
refractive index
1.6 · 1.6000 (estimate)
storage temp.
Keep in dark place,Sealed in dry,Room Temperature
solubility
4 OH · NH4OH 1 M: 50 mg/mL, clear, red
pka
0.6 · pKa 0.6(H2O t = 20 I < 0.001) (Uncertain);2.4(H2O t = 20 I < 0.001) (Uncertain);9.7(H2O t = 20 I < 0.001) (Uncertain);11.8(H2O t = 20 I < 0.001) (Uncertain)
form
powder
color
Orange
Water Solubility
0.1 g/100 · <0.1 g/100 mL at 25 ºC
Merck
14 · 14,8942
BRN
356241 · 356241
BCS Class
2 · 2,4
Stability
1 year · Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 1 month.
Major Application
forensics and toxicologypharmaceutical (small molecule)
InChI
1S/C18H14N4O5S/c23-16-9-6-13(11-15(16)18(24)25)21-20-12-4-7-14(8-5-12)28(26,27)22-17-3-1-2-10-19-17/h1-11,23H,(H,19,22)(H,24,25)/b21-20+
InChIKey
NCEXYHBECQHGNR-QZQOTICOSA-N
SMILES
OC(=O)c1cc(ccc1O)\N=N\c2ccc(cc2)S(=O)(=O)Nc3ccccn3
Toxicology and Carcinogenesis
Toxicology and Carcinogenesis Studies of Salicylazosulfapyridine (CASRN 599-79-1) in F344 Rats and B6C3F1 Mice (Gavage Studies)
CAS DataBase Reference
599 · 599-79-1(CAS DataBase Reference)
FDA UNII
3 XC8GUZ6CB · 3XC8GUZ6CB
Proposition 65 List
Sulfasalazine (salicylazosulfapyridine)
NCI Drug Dictionary
Azulfidine
ATC code
7 EC01 · A07EC01
IARC
2 B · 2B (Vol. 108) 2016
EPA Substance Registry System
Salicylazosulfapyridine (599-79-1)
UNSPSC Code
41116107 · 41116107
NACRES
24 · NA.24
Protein binding
95 · 95-99%
Excreted unchanged in urine
10 · 10-15%
Volume of distribution
5.9 · 5.9-9.1(L/kg)
Biological half-life
18 · 18 / -
Symbol(GHS)
8 · GHS08
Signal word
Danger
Hazard statements
317 · H317-H334
Precautionary statements
261 · P261-P272-P280-P284-P302+P352-P333+P313
PPE
95 · dust mask type N95 (US), Eyeshields, Faceshields, Gloves
Hazard Codes
Xn
Risk Statements
42 · 42/43
Safety Statements
22 · 22-29/56-45
RIDADR
3077 · 3077
WGK Germany
2 · 2
RTECS
6250000 · VO6250000
F
8 · 8
HS Code
2933399090 · 2933399090
Storage Class
11 · 11 - Combustible Solids
Hazard Classifications
2 Carc · Aquatic Chronic 2Carc. 2Repr. 2Resp. Sens. 1Skin Sens. 1
Hazardous Substances Data
599 · 599-79-1(Hazardous Substances Data)
Toxicity
50 oral · LD50 oral in rabbit: > 7500mg/kg
Metabolism/Metabolites · 1 item

In the intestine, sulfasalazine is metabolized by intestinal bacteria to sulfapyridine and 5-aminosalicylic acid. Of the two species, sulfapyridine is relatively well absorbed from the intestine and highly metabolized, while 5-aminosalicylic acid is much less well absorbed.Approximately 15% of a dose of sulfasalazine is absorbed as the parent drug and is metabolized to some extent in the liver to the same two species.Sulfapyridine can also be metabolized to 5-hydroxysulfapyridine and N-acetyl-5-hydroxy sulfapyridine. 5-aminosalicylic acid is primarily metabolized in both the liver and intestine to N-acetyl-5 aminosalicylic acid via a non-acetylation phenotype-dependent route.

Absorption, Distribution and Excretion · 4 items

Following oral administration of 1 g of sulfasalazine to 9 healthy males, less than 15% of a dose of sulfasalazine is absorbed as the parent drug. Detectable serum concentrations of sulfasalazine have been found in healthy subjects within 90 minutes after ingestion. Maximum concentrations of sulfasalazine occur between 3 and 12 hours post-ingestion, with the mean peak concentration (6 μg/mL) occurring at 6 hours.

Absorbed sulfapyridine and 5-aminosalicylic acid and their metabolites are primarily eliminated in the urine either as free metabolites or as glucuronide conjugates. The majority of 5-ASA stays within the colonic lumen and is excreted as 5-aminosalicylic acid and acetyl-5-aminosalicylic acid in the feces.

Following intravenous injection, the calculated volume of distribution for sulfasalazine was 7.5 ± 1.6 L.

The calculated clearance of sulfasalazine following intravenous administration was 1 L/hr. Renal clearance was estimated to account for 37% of total clearance.

Applications · 8 items

DescriptionSulfasalazine (brand name Azulfidine in the U.S., Salazopyrin and Sulazine in Europe and Hong Kong) was developed in the 1950s specifically to treat rheumatoid arthritis. It was believed at the time that bacterial infections were the cause of rheumatoid arthritis. Sulfasalazine is a sulfa drug, (a derivative of mesalazine) and is formed by combining sulfa pyridine and salicylate with an azo bond. It may be abbreviated SSZ.

UsesAnti-inflammatory (gastrointestinal). Has been used in granulomatous colitis.

Usesanticolitis and Crohn's disease

UsesSulfasalazine is an anti-inflammatory (gastrointestinal). Sulfasalazine has been used in granulomatous colitis.

UsesSulfasalazine is a prodrug of the anti-inflammatory agent 5-aminosalicylic acid that is covalently linked to the antibiotic sulfapyridine by an azo bond. This bond is rapidly cleaved by bacteria in the terminal ileum and colon, thus releasing the active anti-inflammatory component. It has long been used in treatment of inflammatory bowel disease and rheumatoid arthritis because of its ability to induce T lymphocyte apoptosis, modulate inflammatory mediators from both cyclooxygenase/5-lipoxygenase pathways and NF-κB signaling pathways, attenuate transcription of proinflammatory cytokines, and activate PPARγ.[Cayman Chemical]

UsesAn inhibitor of of GSH-H-transferase and NF-kB activation and an apoptosis inducer

General DescriptionOdorless yellow or brownish-yellow to orange powder. Tasteless.

General DescriptionSulfasalazine (Azufidine) is an azo prodrug that is reducedby the bacterium present in the lower intestine to its activemetabolites, sulfapyridine and 5-aminosalicylic acid (5-ASA or mesalamine). It has been used for the treatment ofRA or ankylosing spondylitis, and inflammatory bowel diseases(IBDs) such as ulcerative colitis and Crohn disease.It is generally agreed that the therapeutic effects of sulfasalazinein treating IBDs are due mainly through its activemetabolite, 5-ASA. 5-ASA is believed to work, via similarmechanisms of action to the salicylates discussed earlier, byblocking prostaglandin synthesis in the lower intestine. On the other hand, because 5-ASA is completelyionized and very little of this metabolite can enter into systemiccirculation, the antirheumatic effects of sulfasalazinehave been attributed to its other active metabolite, sulfapyridine. In a more recent study, sulfasalazine and sulfapyridinewere found to inhibit 5-aminoimidazole-4-carboxamideribonucleotide transformylase, an enzyme involved in denovo purine biosynthesis. Sulfasalazine also inhibits neutrophilfunction, reduces immunoglobulin levels, and interfereswith T-cell function via suppression of NF-κB activation. Furthermore, like methotrexate, sulfasalazine hasalso been shown to inhibit osteoclastogenesis, thereby preventingbone erosion in arthritic patients.It should be pointed out that approximately one third of thepatients treated long term with sulfasalazine discontinued thedrug because of dose-related adverse effects including nausea,dyspepsia, vomiting, headache, rash, gastric distress, especiallyin patients on a daily dosage of greater than 4 g (or aserum sulfapyridine levels above 50 mg/mL).

Upstream & downstream products

Upstream raw materials

Benzenesulfonyl chlorideAcetic acid2-AminopyridineSulfapyridineAcetanilide5-Aminosalicylic acid4-Nitroso-N-2-pyridinylbenzenesulfonamideSalicylic acidN-Acetylsulfanilyl chlorideSodium hydroxide

Additional notes

DefinitionChEBI: An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.